zoledronic acid has been researched along with Chondrosarcoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckwalter, JA; Fredericks, DC; Malandra, AE; Morcuende, J; Odgren, PR; Otero, JE; Stevens, JW | 1 |
| Jiang, Z; Li, B; Li, H; Li, Y; Sun, L; Ye, Z; Zhang, J | 1 |
| Addeo, R; Capasso, E; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Guarrasi, R; Mamone, R; Montella, L | 1 |
| Ahrens, H; Gosheger, G; Gouin, F; Hardes, J; Henrichs, M; Lanvers-Kaminzky, C; Streitbuerger, A | 1 |
| Gouin, F; Heymann, D; Ory, B; Rédini, F | 1 |
5 other study(ies) available for zoledronic acid and Chondrosarcoma
| Article | Year |
|---|---|
Osteoclast inhibition impairs chondrosarcoma growth and bone destruction.
Topics: Animals; Bone and Bones; Bone Resorption; Chondrosarcoma; Diphosphonates; Imidazoles; Male; Osteoclasts; Parathyroid Hormone-Related Protein; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta2; Zoledronic Acid | 2014 |
Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Adult; Animals; Bone Neoplasms; Cell Line, Tumor; Cells, Cultured; Chondrosarcoma; Cytotoxicity, Immunologic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, Antigen, T-Cell, gamma-delta; Specific Pathogen-Free Organisms; T-Lymphocyte Subsets; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.
Topics: Aged; Antineoplastic Agents; Chondroma; Chondrosarcoma; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Sacrum; Spinal Neoplasms; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chondrosarcoma; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Formazans; Humans; Imidazoles; Male; Tetrazolium Salts; Zoledronic Acid | 2011 |
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Caspase 1; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Chondrosarcoma; Curettage; Diphosphonates; Disease Progression; Imidazoles; Male; Neoplasm Recurrence, Local; Rats; Rats, Sprague-Dawley; Survival Analysis; Zoledronic Acid | 2006 |